Freitag, 13.07.2018 16:55 von PR Newswire | Aufrufe: 83

Rev. Fr. Emmanuel Lemelson Calls on Congress, Office of Inspector General to Investigate SEC Failures

Ein Team-Meeting eines Start-ups. pixabay.com

PR Newswire


MARLBOROUGH, Mass., July 13, 2018 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson, the CIO of Lemelson Capital Management, LLC, a U.S.-based global Investment management firm, today released a letter he has provided members of The U.S. House Committee on Oversight and Government Reform, U.S. House of Representatives Financial Services Committee, The U.S. Senate Committee on Banking, Housing, & Urban Affairs, The U.S. Senate Special Committee on Aging and the SEC Office of the Inspector General, outlining extensive alleged accounting, and securities fraud and abuse of federal and state healthcare laws by Ligand Pharmaceuticals (NASDAQ: LGND), a U.S.-based publicly-traded pharmaceutical company.  In the letter, Lemelson urged the Committees in both the House and the Senate to commence an investigation into these alleged abuses, as well as the Securities and Exchange Commissions (SEC) failure to stop them despite being provided abundant evidence of the alleged fraud spanning multiple years – failures he likens to the Commission's botched Enron and Madoff investigations that allowed these frauds to cost investors and the American taxpayers dearly.

"We believe the greatest risk investors in Ligand face is the company may be excluded from government healthcare programs, found in violation of government regulations and face civil and criminal penalties that could result in imprisonment," Lemelson said.  "It is inexplicable why the SEC has failed to act, given all of the disturbing developments that have been charted.  Protecting the American investor and taxpayer, not to mention the sick who need reliable, affordable access to lifesaving medications must be a priority over fostering cozy relationships with Wall Street," Lemelson continued.

The full letter, is available online here:  https://www.scribd.com/document/383785855/Rev-Fr-Emmanuel-Lemelson-Calls-on-Congress-Office-of-Inspector-General-to-Investigate-SEC-Failures

A copy of Fr. Emmanuel's December 2016 letter to the U.S. Senate Special Committee on Aging, is available online here:

https://amvona.com/featured/finding-alpha/item/43503-lantern-foundation-founder-urges-senate-committee-to-commence-investigation-into-ligand-pharmaceuticals

About Rev. Fr. Emmanuel Lemelson:

Rev. Fr. Emmanuel Lemelson is the Chief Investment Officer of Lemelson Capital Management, LLC a Massachusetts-based Global Investment Management firm.

Kurse

  
106,50
+0,85%
Ligand Pharmaceuticals Chart

For more information, see:  https://www.lemelsoncapital.com/

Lemelson Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 164969.

For further information, please contact:

Lemelson Capital Management, LLC 
Investor and Media Relations 
Telephone: 508-630-2281

Cision View original content:http://www.prnewswire.com/news-releases/rev-fr-emmanuel-lemelson-calls-on-congress-office-of-inspector-general-to-investigate-sec-failures-300680700.html

SOURCE Lemelson Capital Management, LLC

Werbung
Mehr Nachrichten zur Commerzbank Aktie kostenlos abonnieren
E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptieren Sie die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Andere Nutzer interessierte auch dieser Artikel: